Suppr超能文献

印度德里地区出现广泛耐药结核分枝杆菌临床分离株及其分子特征。

Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.

机构信息

Department of Biotechnology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, India.

出版信息

Antimicrob Agents Chemother. 2010 Nov;54(11):4789-93. doi: 10.1128/AAC.00661-10. Epub 2010 Aug 16.

Abstract

We screened 194 Mycobacterium tuberculosis strains isolated from tuberculosis (TB) patients in Delhi and neighboring regions in India to identify the prevalence of extensive drug resistance (XDR) in clinical isolates. Among these, 104 isolates were found to be multidrug resistant (MDR), and 6 were identified as XDR isolates, which was later confirmed by antimicrobial susceptibility testing against the respective drug screening panel. Genotyping was carried out by amplifying and sequencing the following genes: rpoB (rifampin), katG (isoniazid), gyrA (fluoroquinolones), and rrs (amikacin, kanamycin, and capreomycin). Our analyses indicated that mutations at the hot spots of these genes were positively correlated with drug resistance in clinical isolates. The key mutation observed for rpoB was in the codon for amino acid position 531 (S531L), and other mutations were seen in the hot spot, including those encoding Q510P, L511H, D516V, and H526Y mutations. We identified S315T and R463L substitutions encoded in the katG locus. An S95T substitution encoded in the gyrA locus was the most common mutation observed in fluoroquinolone-resistant isolates. In addition, we saw D94G and D94N mutations encoded in the QRDR region. The 16S rRNA (rrs) gene encoded mainly the A1401G mutation and an additional mutation, G1484T, resulting in ribosomal modifications. Taken together, the data in this report clearly establish the presence of phenotypically distinct XDR strains in India by molecular profiling and further identify specific mutational hot spots within key genes of XDR-TB strains.

摘要

我们对来自印度德里及周边地区的 194 株结核分枝杆菌(Mycobacterium tuberculosis)菌株进行了筛查,以确定临床分离株中广泛耐药(extensive drug resistance,XDR)的流行情况。其中 104 株为耐多药(multidrug resistant,MDR)菌株,6 株被鉴定为 XDR 分离株,这一结果后来通过对相应药物筛选板的药敏试验得到了证实。基因分型是通过扩增和测序以下基因来进行的:rpoB(利福平)、katG(异烟肼)、gyrA(氟喹诺酮类)和 rrs(阿米卡星、卡那霉素和卷曲霉素)。我们的分析表明,这些基因热点突变与临床分离株的耐药性呈正相关。rpoB 观察到的关键突变位于密码子 531 位的氨基酸位置(S531L),在热点区还观察到其他突变,包括编码 Q510P、L511H、D516V 和 H526Y 突变。我们鉴定出 katG 基因座编码的 S315T 和 R463L 取代。gyrA 基因座编码的 S95T 取代是氟喹诺酮类耐药分离株中最常见的突变。此外,我们还观察到 QRDR 区域编码的 D94G 和 D94N 突变。16S rRNA(rrs)基因主要编码 A1401G 突变和导致核糖体修饰的额外突变 G1484T。总之,本报告中的数据通过分子谱分析明确证实了印度存在表型上明显不同的 XDR 菌株,并进一步确定了 XDR-TB 菌株关键基因中的特定突变热点。

相似文献

1
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Antimicrob Agents Chemother. 2010 Nov;54(11):4789-93. doi: 10.1128/AAC.00661-10. Epub 2010 Aug 16.
3
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Diagn Microbiol Infect Dis. 2013 Jun;76(2):187-96. doi: 10.1016/j.diagmicrobio.2013.02.035. Epub 2013 Apr 2.
7
Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.
Antimicrob Agents Chemother. 2013 Aug;57(8):3857-63. doi: 10.1128/AAC.00102-13. Epub 2013 Jun 3.
10
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
J Microbiol Immunol Infect. 2016 Jun;49(3):439-44. doi: 10.1016/j.jmii.2015.04.003. Epub 2015 May 15.

引用本文的文献

1
Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
J Antibiot (Tokyo). 2020 Nov;73(11):780-789. doi: 10.1038/s41429-020-0320-7. Epub 2020 May 29.
2
Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India.
Braz J Infect Dis. 2019 Sep-Oct;23(5):281-290. doi: 10.1016/j.bjid.2019.07.002. Epub 2019 Aug 14.
3
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.
BMC Public Health. 2017 Oct 17;17(1):817. doi: 10.1186/s12889-017-4779-5.
4
Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.
Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16.
6
Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.
8
Drug Resistance Pattern of MTB Isolates from PTB Patients.
Tuberc Res Treat. 2013;2013:862530. doi: 10.1155/2013/862530. Epub 2013 Oct 24.
10
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
PLoS One. 2013;8(2):e55299. doi: 10.1371/journal.pone.0055299. Epub 2013 Feb 4.

本文引用的文献

1
Risk factors for MDR and XDR-TB in a tertiary referral hospital in India.
PLoS One. 2010 Mar 4;5(3):e9527. doi: 10.1371/journal.pone.0009527.
2
Extensively drug-resistant tuberculosis.
Lancet Infect Dis. 2009 Jan;9(1):19-30. doi: 10.1016/S1473-3099(08)70260-3. Epub 2008 Nov 5.
3
Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China.
J Clin Microbiol. 2008 Dec;46(12):4075-7. doi: 10.1128/JCM.00822-08. Epub 2008 Oct 22.
4
Extensively drug-resistant Mycobacterium tuberculosis, India.
Emerg Infect Dis. 2007 Sep;13(9):1429-31. doi: 10.3201/eid1309.070443.
8
Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India.
Antimicrob Agents Chemother. 2002 Feb;46(2):443-50. doi: 10.1128/AAC.46.2.443-450.2002.
10
Molecular genetic analysis of multi-drug resistance in Indian isolates of Mycobacterium tuberculosis.
Mem Inst Oswaldo Cruz. 1998 Sep-Oct;93(5):589-94. doi: 10.1590/s0074-02761998000500006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验